Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002005369-25-000004
Filing Date
2025-07-29
Accepted
2025-07-29 13:21:24
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12088
  Complete submission text file 0002005369-25-000004.txt   14017
Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Subject) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91605 | Film No.: 251159933
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022
Business Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 212-371-1717
Invus Global Management, LLC (Filed by) CIK: 0002005369 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A